AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

- 1. (Previously Presented) A method of preparing autologous T-lymphocytes for re-introduction into a patient having cancer, which method comprises:
- (i) obtaining peripheral blood mononuclear cells (PBMCs) from a patient immunized with an antigen of the cancer,
 - (ii) stimulating the PBMCs with the antigen of the cancer in vitro, and
- (iii) transducing the PBMCs with a retroviral vector, which (a) comprises and expresses a human interleukin-2 (IL-2) coding sequence operably linked to a retroviral promoter, (b) does not comprise an exogenously introduced gene that enables phenotypic selection, and (c) comprises a viral envelope that efficiently transduces CD8+ T-lymphocytes,

whereupon autologous T-lymphocytes are prepared for re-introduction into a patient having cancer.

- 2. (Original) The method of claim 1, wherein the cancer is melanoma.
- 3. (Original) The method of claim 2, wherein the antigen of the cancer is gp100.
- 4. (Previously Presented) The method of claim 3, wherein the antigen is the 209-2M peptide (SEQ ID NO: 5).
 - 5. (Original) The method of claim 1, wherein the cancer is breast cancer.
- 6. (Original) The method of claim 5, wherein the antigen of the cancer is Her-2/Neu.
 - 7. (Original) The method of claim 1, wherein the cancer is prostate cancer.
- 8. (Original) The method of claim 7, wherein the antigen of the cancer is prostate-specific antigen (PSA).
 - 9. (Original) The method of claim 1, wherein the cancer is colon cancer.

- 10. (Original) The method of claim 9, wherein the antigen of the cancer is carcinoembryonic antigen (CEA).
- 11. (Previously Presented) The method of claim 1, wherein the viral envelope protein is Gibbon ape leukemia virus envelope (GALV).
- 12. (Previously Presented) The method of claim 1, wherein the retroviral vector further comprises and expresses a human IL-2 receptor α -chain coding sequence.
- 13. (Previously Presented) The method of claim 1, wherein the method further comprises introducing into the PBMCs a vector comprising and expressing a human IL-2 receptor α -chain coding sequence operably linked to a promoter.
 - 14. (Canceled).
- 15. (Withdrawn) A method of treating a patient having cancer, which method comprises administering to the patient autologous T lymphocytes, which have been prepared in accordance with the method of claim 1, in an amount sufficient to treat the patient for cancer.
- 16. (Withdrawn) A method of treating a patient having cancer, which method comprises administering to the patient autologous T lymphocytes, which have been prepared in accordance with the method of claim 1, alone or in further combination with human IL-2 receptor α -chains, in amounts sufficient to treat the patient for cancer.
 - 17, 32. (Canceled).